生物标志物特征引导的精准医学临床试验设计
针对靶向治疗可能无法精确命中靶点、受益人群不确定的问题,提出一种IIB/III期临床试验设计,通过精准识别生物标志物特征筛选敏感患者入组,并采用贝叶斯方法进行响应自适应随机化,结合逆概率加权分析控制选择偏倚和I类错误率。模拟显示该设计在几乎不牺牲统计功效的情况下最大化试验参与者获益,提高试验内总体缓解率和接受最优治疗的患者比例。
要点
- 提出生物标志物特征引导的IIB/III期试验设计以精准筛选敏感患者。
- 采用贝叶斯响应自适应随机化提高参与者接受最优治疗的概率。
- 逆概率加权分析控制选择偏倚和I类错误率。
核心结论
- 模拟显示该设计能在几乎不牺牲统计功效的情况下最大化试验参与者获益,关键优势包括提高试验内总体缓解率和接受最优治疗的患者比例。
研究设计与样本
- 提出一种IIB/III期临床试验设计,旨在精准识别生物标志物特征并选择性入组敏感患者。
- 采用贝叶斯方法进行响应自适应随机化,并使用逆概率加权分析避免选择偏倚和控制I类错误率。
- 基于统计功效、所有参与患者的缓解率、个体损失以及当前和未来患者接受最优治疗的概率四项标准评估设计。
主要发现
- 模拟表明该设计在几乎不牺牲统计功效的情况下最大化试验参与者获益。
- 关键优势包括提高试验内总体缓解率和接受最优治疗的患者比例。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted cancer therapies aim to effectively treat patients with specific biomarker profiles. Nevertheless, these therapies may not always precisely hit their intended targets, leading to uncertainty about the specific subset of patients who will benefit. To address this uncertainty, the identification of sensitive patient subsets in clinical trials becomes crucial. Our proposed phase IIB/III clinical trial design seeks to pinpoint a biomarker signature with precision, ensuring the accurate identification of patients who will respond to a specific treatment. This approach allows for the selective enrollment of sensitive patients to maximize benefits for trial participants. We incorporate Bayesian methodology to facilitate response-adaptive randomization, enhancing the likelihood that each participant receives his/her optimal treatment. Furthermore, our design uses inverse-probability-of-treatment-weighted analysis to avoid selection bias and control for the type I error rate. The evaluation of this trial design is based on four criteria: the statistical power, response rate of all patients participating in the current trial, their individual loss, and probabilities of receiving their optimal treatment for both current trial participants and future patients. Simulations demonstrate the proposed design's potential for maximizing trial participants' benefits with little sacrifice on statistical power. Its key advantages include an improved overall response rate within the trial and a higher percentage of patients receiving the optimal treatment.
引用
- Li Y, Lai D, Li R, et al. A Biomarker Signature-Guided Clinical Trial Design for Precision Medicine. Stat Med. 2025. PMID: 40405471. doi:10.1002/sim.70103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。